Biotechnology
(BIIB) Biogen Analyst Neutral on Shares
We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex,...
21Jan2012 | vitalstocks | 0 comments | Continued(ILMN) Two Major Biotech Trends In 2012
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood...
19Jan2012 | InvestmentU | 0 comments | Continued(CELG) Celgene Corporation – Bull of the Day
We are maintaining our Outperform recommendation on Celgene Corp. (CELG) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS up 36%). Preliminary adjusted revenues in the final quarter of 2011 came in...
18Jan2012 | vitalstocks | 0 comments | Continued(VPHM) ViroPharma Drug Earns Priority Review
ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s approval for the treatment of prevention, pre-procedure prevention, and...
16Jan2012 | vitalstocks | 0 comments | Continued(QGEN) Qiagen Expands with New Deals
In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement,...
13Jan2012 | vitalstocks | 0 comments | Continued(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot
InterMune, Inc. (ITMN) recently reported preliminary fourth quarter revenue for its potential blockbuster drug Esbriet. Esbriet is approved in the European Union (EU) for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF). The drug has been launched first in...
13Jan2012 | vitalstocks | 0 comments | Continued(ALNY) Alnylam States Preclinical Data
Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic...
3Jan2012 | vitalstocks | 0 comments | Continued(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union
Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines Agency (EMA) cleared Dificlir for the treatment of clostridium difficile-associated...
15Dec2011 | vitalstocks | 0 comments | Continued(OPTR) Optimer Pharmaceuticals Moved Down to Neutral
We recently downgraded our rating on Optimer Pharmaceuticals Inc. (OPTR) to Neutral from Outperform as we await more visibility on how the commercial launch of its sole marketed antibiotic Dificid (fidaxomicin) takes shape. Optimer launched Dificid in July 2011 in the US for...
14Dec2011 | vitalstocks | 0 comments | Continued(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress
Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA), a rare genetic enzyme deficiency disorder. The company intends to evaluate...
14Dec2011 | vitalstocks | 0 comments | Continued(MITI) Micromet Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Micromet, Inc. (MITI) with a target price of $7.00 per share following appraisal of third quarter 2011 results. Micromet’s third quarter 2011 loss per share came in at 21 cents (after adjusting for the change in fair value of warrants),...
9Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish
We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological...
8Dec2011 | vitalstocks | 0 comments | Continued(MITI) Micromet Begins New Trial
Micromet Inc. (MITI) recently announced that it has begun a mid-stage registrational trial of its lead pipeline candidate, blinatumomab, in adult patients with B-precursor relapsed refractory acute lymphoblastic leukemia (ALL). The trial was advised to be conducted by the US...
6Dec2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment
Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study...
2Dec2011 | vitalstocks | 0 comments | Continued(GILD) Gilead’s Eviplera Drug is Cleared by European Medicines Agency
Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed...
30Nov2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data
Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation...
28Nov2011 | vitalstocks | 0 comments | Continued(ITMN) InterMune Reports Quarterly Loss Smaller Than Estimates
InterMune, Inc. (ITMN) posted third-quarter adjusted loss per share of 63 cents, wider than the year-ago loss per share of 44 cents due to higher operating expenses. The loss was, however, narrower than the Zacks Consensus Estimate of a loss per share of 73 cents resulting from...
10Nov2011 | vitalstocks | 0 comments | Continued(MDVN) Medivation Incorporated – Bull of the Day
Medivation, Inc. (MDVN) shares received a major boost recently with the company and its partner, Astellas, reporting impressive data on MDV3100 from a pre-specified interim analysis of a phase III study, AFFIRM. The Independent Data Monitoring Committee (IDMC) recommended that...
7Nov2011 | vitalstocks | 0 comments | Continued(DNDN) Dendreon Loss Narrows
Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus Estimate of 70 cents due to a slightly better-than-expected performance...
6Nov2011 | vitalstocks | 0 comments | Continued(VPHM) ViroPharma Going Strong
ViroPharma Inc. (VPHM) posted third quarter 2011 earnings (including special items) of 35 cents per share, surpassing the Zacks Consensus Estimate of 33 cents, but lower than the year-ago figure of 45 cents. Excluding special items, but including stock based compensation expense,...
4Nov2011 | vitalstocks | 0 comments | Continued(THRX) Theravance Third Quarter Loss Deteriorates
Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research...
2Nov2011 | vitalstocks | 0 comments | Continued(HGSI) Human Genome Sciences – Bear of the Day
We are downgrading Human Genome Sciences Inc. (HGSI) to Underperform from Neutral following the disappointing third quarter 2011 results reported by the company. The company suffered a wider-than-expected loss due to lower revenues. The most alarming factor was the below-par...
1Nov2011 | vitalstocks | 0 comments | Continued(CELG) Celgene Corporation – Bull of the Day
We are upgrading Celgene Corporation (CELG) to Outperform from Neutral following strong second quarter results delivered by the company and the decision of CHMP that the benefits associated with Revlimid outweigh the risks in multiple myeloma patients. Celgene performed impressively...
26Oct2011 | vitalstocks | 0 comments | Continued(AMLN) Amylin Pharmaceuticals Posts Lower Loss
Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third...
25Oct2011 | vitalstocks | 0 comments | Continued(CTIC) Cell Therapeutics Incorporated – Bull of the Day
In late September, Cell Therapeutics (CTIC) announced that a second independent radiologic review of data from the pivotal trial PIX301 of lead drug pixantrone for aggressive NHL confirmed the statistical significance of response and progression endpoints. With this positive...
13Oct2011 | vitalstocks | 0 comments | Continued(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress
Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates...
6Oct2011 | vitalstocks | 0 comments | Continued(ACOR) Company News for October 6, 2011 – Corporate Summary
• Monsanto Co. (NYSE:MON) reported its fiscal fourth-quarter loss of $0.22 cents a share, better than the Zacks Consensus Estimate of a loss of $0.27. Revenues rose 15.1% year-over-year to $2.25 billion from $1.95 billion • Reacting to news that Microsoft (NASDAQ:MSFT)...
6Oct2011 | vitalstocks | 0 comments | Continued(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut
Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second...
27Sep2011 | vitalstocks | 0 comments | Continued(MNTA) Momenta Pharmaceuticals and Novartis AG Sue Watson Pharmaceuticals
Momenta Pharmaceuticals, Inc. (MNTA) and Novartis AG (NVS) filed a lawsuit against Amphastar Pharmaceuticals, Inc. and Watson Pharmaceuticals Inc. (WPI) regarding the generic version of Sanofi-Aventis’ (SNY) Lovenox. The lawsuit was filed in United States District Court for...
24Sep2011 | vitalstocks | 0 comments | Continued(MRX) Medicis Pharmaceutical Sells LipoSonix Business
Medicis Pharmaceutical Corp. (MRX) recently announced to have entered into a ‘Stock Purchase Agreement’ with Solta Medical, Inc. (SLTM), under which the latter will acquire all the outstanding shares of Medicis Technologies Corporation (formerly LipoSonix, Inc.), a subsidiary...
20Sep2011 | vitalstocks | 0 comments | Continued